Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATIS: Ruxolitinib and Fostamatinib for COVID-19 Pneumonia
NCT04581954Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Oct 2020
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib, fostamatinib in COVID-19 pneumonia, sponsored by Imperial College London. Started Oct 2020; status: completed.
02
Drugs
ruxolitinibfostamatinib
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04581954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04581954.